猴头菌多醇A | 156101-08-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 猴头菌多醇A
• 英文名称: erinacine A
• 英文别名: (+)-Erinacin A；(3aR,5aR,6S)-3a,5a-dimethyl-1-propan-2-yl-6-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-2,3,4,5,6,7-hexahydrocyclohepta[e]indene-8-carbaldehyde
• CAS: 156101-08-5
• 化学式: C₂₅H₃₆O₆
• 分子量: 432.557
• InChiKey: LPPCHLAEVDUIIW-NLLUTMDRSA-N

物化性质

• 沸点：
  610.8±55.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  96.2
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2,6,7,7a-tetrahydro-7a-methyl-3-(1-methylethyl)-5-trifluoromethylsulfonyl-oxy-1H-indene 在 咪唑 、 六甲基磷酰三胺 、 manganese(IV) oxide 、 palladium diacetate 、 四氧化锇 、 lithium aluminium tetrahydride 、 三甲基氯硅烷 、 苯基氯化硒 、 potassium metaperiodate 、 copper(I) bromide dimethylsulfide complex 、 potassium tert-butylate 、 双氧水 、 二甲基氯化铝 、 氰化汞 、 双(三甲基硅烷基)氨基钾 、 二异丁基氢化铝 、 potassium carbonate 、 溶剂黄146 、 三乙胺 、 N,N-二异丙基乙胺 、 三苯基膦 、 mercury dichloride 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 甲醇 、 乙腈 为溶剂， 反应 0.06h， 生成 猴头菌多醇A
  参考文献：
  名称：

  Synthesis of (±)-Allocyathin B₂ and (+)-Erinacine A

  摘要：

  DOI：

  10.1021/ja9615379

文献信息

• Isolation of erinacine P, a new parental metabolite of cyathane-xylosides, from Hericium erinaceum and its biomimetic conversion into erinacines A and B
  作者：Hiromichi Kenmoku、Takeshi Sassa、Nobuo Kato

  DOI：10.1016/s0040-4039(00)00601-8

  日期：2000.6

  A new cyathane-xyloside, erinacine P, was isolated from mycelia of basidiomycetous Hericium erinaceum YB4-6237 in a shaken culture. Since its aglycon closely resembles typical cyathane diterpenoids such as cyathins and cyathatriols in its substitution pattern, this glycoside seems to be an important metabolite in the biosynthesis of erinacines and striatins. In fact, according to our biogenesis studies, erinacine P can be successfully converted chemically into erinacine B and, further, to erinacine A under mild conditions. (C) 2000 Elsevier Science Ltd. All rights reserved.
• COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID
  申请人：CaaMTech, LLC

  公开号：US20190142851A1

  公开（公告）日：2019-05-16

  This disclosure pertains to new compositions and methods comprising a psilocybin derivative. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, or purified terpene.
• TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH
  申请人：STAMETS Paul Edward

  公开号：US20210069170A1

  公开（公告）日：2021-03-11

  Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum ) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica , or Cannabis ruderalis , optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.
• COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND
  申请人：CAAMTECH, INC.

  公开号：US20210346346A1

  公开（公告）日：2021-11-11

  Disclosed herein are compositions comprising a serotonergic tryptamine compound, combinations thereof, and methods of using them for treating and preventing a variety of human conditions. In one embodiment, disclosed herein are new compositions and methods which comprise a therapeutically effective amount of a first purified psilocybin derivative and a therapeutically effective amount of a second compound. The second compound is selected from the group consisting of a second purified psilocybin derivative, a purified terpene, a serotonergic drug, an adrenergic drug, a dopaminergic drug, a purified erinacine, and a purified hericenone.
• [EN] TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH<br/>[FR] COMPOSITIONS DE TRYPTAMINES DESTINÉES À AMÉLIORER L'EXCROISSANCE DES NEURITES
  申请人：STAMETS PAUL EDWARD

  公开号：WO2021101926A1

  公开（公告）日：2021-05-27

  Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.